P4HA1 and Myocardial fibrosis: Zhao et al. found that liraglutide can upregulate the expression levels of CD36 and p-JNK, enhance the DNA-binding activity of activator protein (AP)-1 to P4HA1, thereby downregulating P4HA1 expression and reducing myocardial fibrosis (Zhao et al., 2019).